Changes in the Incidence of Invasive Pneumococcal Disease in Calgary, Canada, during the SARS-CoV-2 Pandemic 2020-2022.

Leah J Ricketson, James D Kellner
Author Information
  1. Leah J Ricketson: Department of Pediatrics, University of Calgary, Calgary, AB T2N 1N4, Canada. ORCID
  2. James D Kellner: Department of Pediatrics, University of Calgary, Calgary, AB T2N 1N4, Canada. ORCID

Abstract

We describe the impact of non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic on invasive pneumococcal disease (IPD) in Calgary. IPD declined significantly worldwide during 2020 and 2021. This may be due to the reduced transmission of and decrease in circulating viruses that often co-infect with the opportunistic pneumococcus. Pneumococcus has not been shown to frequently co-infect or cause secondary infection with SARS-CoV-2. We examined and compared incidence rates in Calgary per quarter in the pre-vaccine, post-vaccine, 2020 and 2021 (pandemic) and 2022 (late pandemic) eras. We also conducted a time series analysis from 2000-2022 allowing for change in trend at introduction of vaccines and for initiation of NPIs during the COVID-19 pandemic. Incidence declined in 2020/2021 but by the end of 2022 had begun to rapidly recover to near pre-vaccine rates. This recovery may be related to the high rates of viral activity in the winter of 2022 along with childhood vaccines being delayed during the pandemic. However, a large proportion of the IPD caused in the last quarter of 2022 was serotype 4, which has caused outbreaks in the homeless population of Calgary in the past. Further surveillance will be important to understand IPD incidence trends in the post-pandemic landscape.

Keywords

References

  1. Clin Infect Dis. 2022 Jan 29;74(2):335-338 [PMID: 33907808]
  2. Nat Rev Microbiol. 2023 Mar;21(3):195-210 [PMID: 36253478]
  3. Clin Infect Dis. 2021 Mar 1;72(5):e65-e75 [PMID: 33196783]
  4. Front Microbiol. 2017 Jun 23;8:1041 [PMID: 28690590]
  5. Can J Public Health. 2021 Aug;112(4):620-628 [PMID: 34047965]
  6. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1305-1309 [PMID: 32941415]
  7. Emerg Infect Dis. 2022 Aug;28(8):1669-1672 [PMID: 35876698]
  8. Pediatr Pulmonol. 2020 Sep;55(9):2198-2200 [PMID: 32602267]
  9. JAMA Netw Open. 2022 Jun 1;5(6):e2218959 [PMID: 35763298]
  10. Am J Infect Control. 2023 Apr;51(4):475-477 [PMID: 36115540]
  11. Eur Respir J. 2021 Nov 4;58(5): [PMID: 34289978]
  12. Open Forum Infect Dis. 2019 Oct 1;6(10): [PMID: 31419302]
  13. PLoS One. 2021 Jun 18;16(6):e0253451 [PMID: 34143839]
  14. Clin Infect Dis. 2014 Jan;58(2):188-94 [PMID: 24190895]
  15. Emerg Infect Dis. 2021 Jul;27(7):1867-1875 [PMID: 34152965]
  16. Can Commun Dis Rep. 2023 Feb 01;49(23):81-86 [PMID: 38088953]
  17. BMC Infect Dis. 2021 Feb 22;21(1):199 [PMID: 33618663]
  18. Pediatrics. 2021 Jul;148(1): [PMID: 33858983]
  19. Mt Sinai J Med. 1976 Nov-Dec;43(6):699-709 [PMID: 13297]
  20. Clin Infect Dis. 2009 Jul 15;49(2):205-12 [PMID: 19508165]
  21. PLoS One. 2011;6(12):e28547 [PMID: 22216100]
  22. Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1353-1355 [PMID: 33462723]
  23. Clin Infect Dis. 2022 Aug 24;75(1):e1154-e1164 [PMID: 34904635]
  24. Med Sci Monit. 2020 Nov 14;26:e928754 [PMID: 33188161]
  25. Trends Microbiol. 2021 Oct;29(10):930-941 [PMID: 33934980]
  26. Am J Emerg Med. 2021 Apr;42:203-210 [PMID: 33279331]
  27. J Pediatric Infect Dis Soc. 2022 Sep 29;11(9):426-428 [PMID: 35731619]
  28. J Microbiol Immunol Infect. 2020 Aug;53(4):505-512 [PMID: 32482366]
  29. Emerg Infect Dis. 2022 Nov;28(11):2321-2325 [PMID: 36220135]
  30. BMJ Open. 2021 Oct 11;11(10):e055575 [PMID: 34635536]
  31. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629 [PMID: 32711058]
  32. Int J Infect Dis. 2021 Oct;111:196-203 [PMID: 34455081]
  33. Lancet Digit Health. 2021 Jun;3(6):e360-e370 [PMID: 34045002]
  34. BMJ Open. 2022 Jan 25;12(1):e055968 [PMID: 35078849]
  35. Lancet Microbe. 2021 Aug;2(8):e354-e365 [PMID: 34100002]
  36. Microorganisms. 2023 May 18;11(5): [PMID: 37317307]
  37. Clin Microbiol Infect. 2021 Jan;27(1):83-88 [PMID: 32745596]
  38. J Infect Dis. 2023 Apr 12;227(7):907-916 [PMID: 36723871]
  39. IUBMB Life. 2020 Oct;72(10):2097-2111 [PMID: 32770825]
  40. J Infect. 2020 Dec;81(6):e19-e21 [PMID: 32810519]
  41. J Infect. 2021 Feb;82(2):282-327 [PMID: 32956735]
  42. Microorganisms. 2022 May 05;10(5): [PMID: 35630415]
  43. Pediatr Infect Dis J. 2018 Jan;37(1):22-27 [PMID: 28737622]
  44. Cureus. 2021 Feb 25;13(2):e13559 [PMID: 33791177]
  45. Clin Infect Dis. 2022 Sep 30;75(7):1149-1153 [PMID: 35136983]

Grants

  1. WI222857/Pfizer (Canada)

Word Cloud

Created with Highcharts 10.0.0pandemicIPDCalgary2022COVID-19SARS-CoV-2incidenceratesNPIsinvasivepneumococcaldiseasedeclined20202021mayco-infectquarterpre-vaccinevaccinesIncidencecauseddescribeimpactnon-pharmaceuticalinterventionssignificantlyworldwideduereducedtransmissiondecreasecirculatingvirusesoftenopportunisticpneumococcusPneumococcusshownfrequentlycausesecondaryinfectionexaminedcomparedperpost-vaccinelateerasalsoconductedtimeseriesanalysis2000-2022allowingchangetrendintroductioninitiation2020/2021endbegunrapidlyrecovernearrecoveryrelatedhighviralactivitywinteralongchildhooddelayedHoweverlargeproportionlastserotype4outbreakshomelesspopulationpastsurveillancewillimportantunderstandtrendspost-pandemiclandscapeChangesInvasivePneumococcalDiseaseCanadaPandemic2020-2022Streptococcuspneumoniae

Similar Articles

Cited By